Mologen
Manufacturing · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Fabeckstr 30, Berlin, Berlin, 14195, Ger...Phone Number
+49 49308417880Website
www.mologen.comRevenue
<$5 MillionStock Symbol
MGNKIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Mologen
Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and human immunodeficiency virus (HIV). The company's lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase III study for the treatment of metastatic colorectal cancer; Phase II trial for the treatment of small-cell lung cancer; and Phase Ib/IIa study of lefitolimod in HIV infected patients under antiretroviral therapy through collaborations with the Aarhus University Hospital in Denmark. Its lead product Lefitolimod is also under Phase I combination study with the checkpoint inhibitor Yervoy to treat advanced solid tumors in collaboration with MD Anderson Cancer Center at the University of Texas, the United States. In addition, the company is involved in the development of EnanDIM molecules, which are under pre-clinical development for cancer/anti-infective therapies; and MGN1601, a cell based therapeutic vaccine, which has completed Phase I/II trial for the treatment of reRead more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mologen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Mologen recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Mologen, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Mologen had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Mologen
Check if Mologen has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Mologen launches new products
Funding: Get notified immidiatlly once Mologen has new funding data
Check out if Mologen is spiking on competitors!
Recommended Actions
Find VP level buyers at Mologen
Find more new buyers
Company Profile Activity
Activity Insights
Mologen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mologen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mologen.
Mologen Tech Stack
A closer look at the technologies used by Mologen
See more technologies
Mologen News & Media
What Kind Of Shareholder Appears On The Mologen AG's (ETR:MGNK) Shareholder Register?
If you want to know who really controls Mologen AG (ETR:MGNK), then you'll have to look at the makeup of its share...MOLOGEN AG Announces Top Line Data of Pivotal IMPALA Study in Metastatic Colorectal Cancer
BERLIN--(BUSINESS WIRE)--The biopharmaceutical company MOLOGEN AG announced today the top line data of its pivotal phase III IMPALA study.MOLOGEN and ONCOLOGIE: Global assignment and co-development agreement relating to MOLOGEN’s lead compound lefitolimod
BERLIN--(BUSINESS WIRE)--MOLOGEN and ONCOLOGIE signed a global assignment and co-development agreement relating to MOLOGEN’s lead compound lefitolimodDr Ignacio Faus appointed as new CEO of MOLOGEN AG
BERLIN--(BUSINESS WIRE)--MOLOGEN AG appointed Dr Ignacio Faus as Member of the Executive Board and new Chief Executive Officer of MOLOGEN AG with effect from August 1, 2018.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mologen
Sign Up For FreeTo access detailed company insights
Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and human immunodeficiency virus (HIV). The company's lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase III study for the treatment of metastatic colorectal cancer; Phase II trial for the treatment of small-cell lung cancer; and Phas... Read More
